Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Last trade$411.39
Day change+$0.10 (+0.02%)
Day range$403.31 – $412.61
Volume124,961
Market cap$46.98B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$46.98B
Price / earnings
51.31×
Price / book
8.07×
Price / sales
7.11×
EV / sales
6.4×
EV / EBITDA
31.15×
Profitability
Earnings per share
$8.02
Return on assets
9.27%
Return on equity
15.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.18×
Current ratio
3.55×
Quick ratio
3.19×
Cash ratio
2.59×
Cash flow
Price / cash flow
29.54×
Price / free cash flow
32.42×
Free cash flow
$1.45B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ONC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$1.89B
$1.71B
$1.51B
$1.5B
$1.41B
$1.32B
$1.12B
Cost of revenue
$216.9M
$174.53M
$167.22M
$142.42M
$196.51M
$164.61M
$165M
Gross profit
$1.67B
$1.53B
$1.35B
$1.36B
$1.22B
$1.15B
$952.28M
Selling, general and administrative
$593.46M
$593.21M
$555.1M
$555.29M
$529M
$537.91M
$459.29M
Research and development
$660.78M
$612.28M
$541.22M
$615.42M
$523.66M
$524.9M
$481.89M
Total operating expenses
$1.25B
$1.21B
$1.1B
$1.17B
$1.05B
$1.06B
$941.18M
Operating income
$418.68M
$325.05M
$249.9M
$185.04M
$163.11M
$87.89M
$11.1M
Interest expense
-$42.41M
-$39.74M
-$32.89M
-$58.23M
-$16.36M
-$8M
-$7M
Income before taxes
$410.36M
$312.46M
$259.22M
$149.24M
$147.16M
$99.55M
$20.9M
Income taxes
$25.65M
$75.45M
$31.86M
$82.74M
$22.32M
$5.23M
$19.63M
Net income
$384.71M
$237.01M
$227.36M
$66.5M
$124.84M
$94.32M
$1.27M
Net income attributable to common shareholders
$384.71M
$237.01M
$227.36M
$66.5M
$124.84M
$94.32M
$1.27M
EBITDA
$479.61M
$365.56M
$291.05M
$221.02M
$200.4M
$123.5M
$43.91M
Basic earnings per share
$0.26
$0.16
$0.16
$0.05
$0.09
$0.07
$0.00
Diluted earnings per share
$0.25
$0.16
$0.15
$0.04
$0.08
$0.06
$0.00
Recent news
Company coverage with links to the original publishers.
Revolution Medicines reported Q3 2026 results with a narrower-than-expected loss of $1.90 per share and revenues of $197.6 million, entirely from Rasonque sales following its FDA approval in late August. The drug reached over 5,000 patients in five weeks with strong reimbursement coverage. The company maintained its 2026 operating expense guidance and holds a strong cash position of $3.7 billion. European approval is pending, and multiple late-stage studies are underway for pancreatic cancer and other RAS-mutant cancers.
Five stocks have been added to the Zacks Rank #1 (Strong Buy) list, including Hewlett Packard Enterprise, AerCap Holdings, Ultrapar Participações, BeOne Medicines, and Bankwell Financial Group. These companies have shown consensus earnings estimate increases ranging from 7.4% to 15.2% over the last 60 days.
The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.
BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy) rating, primarily driven by upward trends in earnings estimates. Over the past three months, the Zacks Consensus Estimate for the company has increased 53.4%. The upgrade positions the stock in the top 5% of Zacks-covered stocks, suggesting potential for near-term price appreciation based on improving earnings outlook.
Jazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.